Raltegravir does not revert efflux activity of MDR1-P-glycoprotein in human MDR cells

BACKGROUND: Raltegravir (Isentress®)(RALT) has demonstrated excellent efficacy in both treatment-experienced and naïve patients with HIV-1 infection, and is the first strand transfer integrase inhibitor to be approved for use in HIV infected adults worldwide. Since the in vivo efficacy of this class...

Descripción completa

Detalles Bibliográficos
Autores principales: Dupuis, Maria Luisa, Ascione, Alessandro, Palmisano, Lucia, Vella, Stefano, Cianfriglia, Maurizio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3852167/
https://www.ncbi.nlm.nih.gov/pubmed/24053678
http://dx.doi.org/10.1186/2050-6511-14-47

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3852167/
https://www.ncbi.nlm.nih.gov/pubmed/24053678
http://dx.doi.org/10.1186/2050-6511-14-47

Ejemplares similares